Selb Regina, Buder Susanne, Dudareva Sandra, Tamminga Thalea, Bremer Viviane, Banhart Sebastian, Heuer Dagmar, Jansen Klaus
Unit 'HIV/AIDS, STI and Blood-borne Infections', Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
Unit 'Sexually Transmitted Bacterial Infections', Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Euro Surveill. 2021 Aug;26(31). doi: 10.2807/1560-7917.ES.2021.26.31.2100616.
We monitored antimicrobial susceptibility developments of in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.
我们监测了2014年1月至2021年5月期间德国的抗菌药物敏感性变化情况。阿奇霉素最低抑菌浓度高于流行病学临界值的分离株比例大幅上升，从2014年的1.3%增至2020年的12.2%。2021年的初步数据显示这一比例进一步上升（1月至5月：20.7%）。因此，在德国，阿奇霉素作为推荐用于依从性差患者的双重治疗方案的一部分受到了挑战。临床实践中的抗菌药物敏感性检测至关重要，持续的敏感性监测不可或缺。
